News – Page 19 – Alligator Bioscience

2021-10-21

Alligator Announces First Patient Dosed in Phase II Clinical Trial with Shanghai Henlius Biotech, Inc. & AbClon, Inc.

Lund, Sweden, October 20, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced that the Company was notified that t ...

2021-10-15

LUND (Sweden) – Alligator Bioscience will host a conference call (in English) investors, analysts and media on Thursday, October 21st, 2021, ...

2021-10-07

The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201 (“Alligator”), are invited to the extraordinary general meeting to be held ...

2021-10-07

Regulatory

The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or "the Company") has today, subject to approval by th ...

2021-09-30

Lund, Sweden, September 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that it has dosed the first patient in it ...

2021-09-22

Lund, Sweden, September 23, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that Søren Bregenholt, Chief Execu ...

2021-09-02

Regulatory

Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that the Company, in order to enabl ...

2021-09-02

Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) and Scandion Oncology A/S (Nasdaq Stockholm: SCOL), toda ...

2021-08-18

Regulatory

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company has entered into a research collaboration and license agreem ...